Login to Your Account



Seattle Genetics, Celltech In $30M Antibody Conjugate Deal

By Karen Young


Friday, March 29, 2002
Celltech Group plc and Seattle Genetics Inc. entered into a multiyear research collaboration to use Seattle Genetics’ antibody-drug conjugate technology with Celltech’s antibody fragments, initially for immunological targets. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription